Literature DB >> 8280909

The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin.

O Tzischinsky1, A Shlitner, P Lavie.   

Abstract

The present study investigated the relationship between the time of nocturnal onset of urinary 6-sulfatoxymelatonin (aMT6s) secretion, and the timing of the steepest increase in nocturnal sleepiness ("sleep gate"), as determined by an ultrashort sleep-wake cycle test (7 min sleep, 13 min wake). Twenty-nine men (mean age 23.8 +/- 2.7 years) participated. The ultrashort sleep-wake paradigm started at 0700 hr after a night of sleep deprivation and continued for 24 hr until 0700 hr the next day. Electrophysiological recordings were carried out during the 7-min sleep trials, which were then scored conventionally for sleep stages. Urinary aMT6s was measured every 2 hr. The results showed that the timing of the sleep gate was significantly correlated with the onset of aMT6s secretion. These results are discussed in light of the possible role of melatonin in sleep-wake regulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280909     DOI: 10.1177/074873049300800303

Source DB:  PubMed          Journal:  J Biol Rhythms        ISSN: 0748-7304            Impact factor:   3.182


  19 in total

1.  Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt.

Authors:  Tali Gorfine; Nava Zisapel
Journal:  Hum Brain Mapp       Date:  2009-02       Impact factor: 5.038

2.  Sleep-wake disturbances in hospitalized patients with traumatic brain injury: association with brain trauma but not with an abnormal melatonin circadian rhythm.

Authors:  Catherine Duclos; Marie Dumont; Jean Paquet; Hélène Blais; Solenne Van der Maren; David K Menon; Francis Bernard; Nadia Gosselin
Journal:  Sleep       Date:  2020-01-13       Impact factor: 5.849

3.  Melatonin, Circadian Rhythms, and Sleep.

Authors:  Irina V. Zhdanova; Valter Tucci
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

4.  Potential of melatonin replacement therapy in older patients with sleep disorders.

Authors:  I Haimov; P Lavie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 5.  Circadian Disruption Associated with Alzheimer's Disease.

Authors:  Yumna Saeed; Sabra M Abbott
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 6.  Understanding sleep-wake behavior and sleep disorders in children: the value of a model.

Authors:  Oskar G Jenni; Monique K LeBourgeois
Journal:  Curr Opin Psychiatry       Date:  2006-05       Impact factor: 4.741

7.  The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study).

Authors:  Birgit C P Koch; J Elsbeth Nagtegaal; E Chris Hagen; Monique M L van der Westerlaken; Jan B S Boringa; Gerard A Kerkhof; Piet M Ter Wee
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 8.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Circadian sleep-wake rhythm disturbances in end-stage renal disease.

Authors:  Birgit C P Koch; J Elsbeth Nagtegaal; Gerard A Kerkhof; Piet M ter Wee
Journal:  Nat Rev Nephrol       Date:  2009-05-26       Impact factor: 28.314

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.